The United Kingdom and the United States have concluded a key bilateral deal that will keep no tariffs on UK drug products entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost expenditure on pharmaceuticals through the public health system. This pledge guarantees that tariffs on these key products will be held at nothing for a period of the next three years.
This development comes after recent statements to dramatically increase duties on branded pharmaceutical imports, with figures mentioned up to double the cost.
"This agreement with the Britain strengthens the global environment for new treatments and introduces long-overdue balance to American-British medicine commerce," an announcement said.
Trade Impact
Pharmaceuticals constitute one of the UK's most significant goods shipped to the America, which is by far the largest destination for large UK drugmakers.
Trade data show that in the 12 months to the end of last September, the UK shipped drugs totaling over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that timeframe.
"This deal protects work, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for biotech and pharma," a minister remarked.
Specific British Pledges
The agreement includes several specific pledges from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it considers new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to raise overall health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. Last year, refunds were more than 20%.
Industry Background
The deal comes amid a ongoing row between the pharmaceutical industry and the ministers over medicine costs and approval rates.
The disagreement were intensified by arguments that US consumers were paying a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or cancelled, while major funding commitments have been pledged toward US facilities.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had decreased as a percentage of its total funding over the previous ten-year period.
